Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise-induced cardiac adaptations in rheumatoid arthritis patients during interleukin-6 vs. tumor necrosis factor antibody therapy (RABEX)
2021-005287-21Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in rheumatoid arthritis (RA) comparing Sarilumab (IL-6 blockade) arm with Adalimumab (TNF blockade) arm (2 arms). Primary endpoint: Primary physiological adaptations to exercise under IL-6 vs TNF blockade. Started Oct 2021; status: completed.
02
Drugs
sarilumabadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-005287-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005287-21.